NEUROPSYCHIATRIC EFFECTS OF ANTIDEPRESSANTS THAT HINDER ADHERENCE AND THERAPEUTIC SUCCESS
DOI:
https://doi.org/10.63330/aurumpub.068-044Keywords:
Adverse effects, Antidepressants, Depression, Discontinuation, Neuropsychiatry, Psychopharmacology, Therapeutic adherenceAbstract
Antidepressants are a primary pharmacological strategy for treating depressive disorders and various neuropsychiatric conditions. Despite their efficacy, adverse effects can compromise adherence, treatment continuity, and, consequently, therapeutic success. Neuropsychiatric manifestations potentially linked to antidepressant use include drowsiness, insomnia, anxiety, agitation, cognitive changes, emotional blunting, sexual dysfunction, mood alterations, and—in certain individuals—symptoms of activation or the precipitation of manic or hypomanic episodes. Furthermore, the abrupt discontinuation of certain drugs can trigger withdrawal symptoms that may lead patients to abandon treatment. This article discusses the main neuropsychiatric effects that can interfere with antidepressant adherence, the underlying mechanisms, risk factors, and clinical strategies to minimize these events. It is important to note that the presence of symptoms during treatment does not necessarily imply they are caused by the antidepressant, as similar manifestations may stem from the psychiatric disorder itself or other clinical conditions.
Downloads
References
1. ANAGHA, K.; SHIHABUDHEEN, P.; UVAIS, N. A. Side effect profiles of selective serotonin reuptake inhibitors: a cross-sectional study in a naturalistic setting. The Primary Care Companion for CNS Disorders, v. 23, n. 4, p. 35561, 2021.
2. ANEKWE, Chika V. et al. Pharmacotherapy causing weight gain and metabolic alteration in Those with obesity and obesity‐related conditions: A review. Annals of the New York Academy Of Sciences, v. 1533, n. 1, p. 145-155, 2024.
3. ASANO, Hiroto et al. Safety comparisons among monoamine oxidase inhibitors against parkinson’s disease using FDA adverse event reporting system. Scientific Reports, v. 13, n. 1, p. 19272, 2023.
4. ATMACA, Murad. Selective serotonin reuptake inhibitor-induced sexual dysfunction: current management perspectives. Neuropsychiatric Disease and Treatment, p. 1043-1050, 2020.
5. BALDAARA, Leonardo; FREITAS, Railson; DE CARVALHO BALDA«ARA, Raquel Prudente. Tricyclic antidepressants: na update. Research, Society and Development, v. 13, n. 4, p.E4413445539-e4413445539, 2024.
6. BARROS, Landerson Guimarães et al. Estudo bibliográfico sobre as potenciais interações medicamentosas envolvendo antidepressivos tricíclicos. E-Acadêmica, v. 3, n. 2, p. e8232244 EVENTOS ADVERSOS RELACIONADOS AO USO DE ANTIDEPRESSIVOS
7. Magalhães et. Al. EVENTOS ADVERSOS RELACIONADOS AO USO DE ANTIDEPRESSIVOS. Brazilian Journal of Implantology and Health Sciences Volume 5, Issue 3 (2023), Page 05-43. E8232244, 2022.
8. CHAMBERLAIN, Samuel R.; BALDWIN, David S. Monoamine oxidase inhibitors (MAOIs) in Psychiatric practice: how to use them safely and effectively. CNS Drugs, v. 35, n. 7, p. 703-716, 2021.
9. CHU, A.; WADHWA, R. Selective Serotonin Reuptake Inhibitors. StatPearls Publishing, jan. 2025.
10. CLIATT, Hayley; WILLIAMS, Andrew M.; KOCH, Jessa. Management of antidepressant-induced Bruxism. Mental Health Clinician, v. 15, n. 3, p. 147-9, 2025.
11. EDINOFF, Amber N. et al. Selective serotonin reuptake inhibitors and adverse effects: a narrative review. Neurology International, v. 13, n. 3, p. 387-401, 2021.
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
